122 related articles for article (PubMed ID: 29508536)
21. Defining the requirements for the pathogenic interaction between mutant calreticulin and MPL in MPN.
Elf S; Abdelfattah NS; Baral AJ; Beeson D; Rivera JF; Ko A; Florescu N; Birrane G; Chen E; Mullally A
Blood; 2018 Feb; 131(7):782-786. PubMed ID: 29288169
[TBL] [Abstract][Full Text] [Related]
22. JAK2, MPL, and CALR mutations in children with essential thrombocythemia.
Sekiya Y; Okuno Y; Muramatsu H; Ismael O; Kawashima N; Narita A; Wang X; Xu Y; Hama A; Fujisaki H; Imamura T; Hasegawa D; Kosaka Y; Sunami S; Ohtsuka Y; Ohga S; Takahashi Y; Kojima S; Shimada A
Int J Hematol; 2016 Aug; 104(2):266-7. PubMed ID: 27209416
[No Abstract] [Full Text] [Related]
23. Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation.
Elf S; Abdelfattah NS; Chen E; Perales-Patón J; Rosen EA; Ko A; Peisker F; Florescu N; Giannini S; Wolach O; Morgan EA; Tothova Z; Losman JA; Schneider RK; Al-Shahrour F; Mullally A
Cancer Discov; 2016 Apr; 6(4):368-81. PubMed ID: 26951227
[TBL] [Abstract][Full Text] [Related]
24. JAK2 V617F, MPL, and CALR Mutations in Korean Patients with Essential Thrombocythemia and Primary Myelofibrosis.
Kim BH; Cho YU; Bae MH; Jang S; Seo EJ; Chi HS; Choi Y; Kim DY; Lee JH; Lee JH; Lee KH; Park YM; Lee JK; Park CJ
J Korean Med Sci; 2015 Jul; 30(7):882-8. PubMed ID: 26130950
[TBL] [Abstract][Full Text] [Related]
25. Philadelphia+ Chronic Myeloid Leukemia with CALR Mutation: A Case Report and Literature Review.
Yoon SY; Jeong SY; Kim C; Lee MY; Kim J; Kim KH; Lee N; Won JH
Cancer Res Treat; 2020 Jul; 52(3):987-991. PubMed ID: 32019282
[TBL] [Abstract][Full Text] [Related]
26. [Development of myeloproliferative neoplasms by mutant calreticulin: underlying mechanisms].
Araki M
Rinsho Ketsueki; 2018; 59(8):1072-1077. PubMed ID: 30185708
[TBL] [Abstract][Full Text] [Related]
27. Systematization of analytical studies of polycythemia vera, essential thrombocythemia and primary myelofibrosis, and a meta-analysis of the frequency of JAK2, CALR and MPL mutations: 2000-2018.
Mejía-Ochoa M; Acevedo Toro PA; Cardona-Arias JA
BMC Cancer; 2019 Jun; 19(1):590. PubMed ID: 31208359
[TBL] [Abstract][Full Text] [Related]
28. Clinical and Hematological Relevance of JAK2V617F, CALR, and MPL Mutations in Vietnamese Patients with Essential Thrombocythemia.
Vu HA; Thao TT; Dong CV; Vuong NL; Chuong HQ; Van PNT; Nghia H; Binh NT; Dung PC; Xinh PT
Asian Pac J Cancer Prev; 2019 Sep; 20(9):2775-2780. PubMed ID: 31554376
[TBL] [Abstract][Full Text] [Related]
29. [Current problems in the diagnosis of Philadelphia-negative myeloproliferative neoplasms in Japan].
Shirane S; Araki M; Morishita S; Edahiro Y; Ohsaka A; Komatsu N
Rinsho Ketsueki; 2015 Jul; 56(7):877-82. PubMed ID: 26251152
[TBL] [Abstract][Full Text] [Related]
30. [New disease markers within the chronic myeloproliferative neoplasms].
Holmström MO; Ocias LF; Kallenbach K; Kjær L; Kristensen TK; Pallisgaard N; Petersen BL; Skov V; de Stricker K; Larsen TS; Hasselbalch HC
Ugeskr Laeger; 2015 May; 177(19):. PubMed ID: 25967091
[TBL] [Abstract][Full Text] [Related]
31. Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms.
Araki M; Yang Y; Masubuchi N; Hironaka Y; Takei H; Morishita S; Mizukami Y; Kan S; Shirane S; Edahiro Y; Sunami Y; Ohsaka A; Komatsu N
Blood; 2016 Mar; 127(10):1307-16. PubMed ID: 26817954
[TBL] [Abstract][Full Text] [Related]
32. Simultaneous screening for JAK2 and calreticulin gene mutations in myeloproliferative neoplasms with high resolution melting.
Matsumoto N; Mori S; Hasegawa H; Sasaki D; Mori H; Tsuruda K; Imanishi D; Imaizumi Y; Hata T; Kaku N; Kosai K; Uno N; Miyazaki Y; Yanagihara K
Clin Chim Acta; 2016 Nov; 462():166-173. PubMed ID: 27693531
[TBL] [Abstract][Full Text] [Related]
33. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
[TBL] [Abstract][Full Text] [Related]
34. Calreticulin exon 9 mutations in myeloproliferative neoplasms.
Ha JS; Kim YK
Ann Lab Med; 2015 Jan; 35(1):22-7. PubMed ID: 25553276
[TBL] [Abstract][Full Text] [Related]
35. Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations.
Al Assaf C; Van Obbergh F; Billiet J; Lierman E; Devos T; Graux C; Hervent AS; Emmerechts J; Tousseyn T; De Paepe P; Papadopoulos P; Michaux L; Vandenberghe P
Haematologica; 2015 Jul; 100(7):893-7. PubMed ID: 25934766
[TBL] [Abstract][Full Text] [Related]
36. Essential thrombocythaemia with mutation in
Alvarez-Larran A; Martínez D; Arenillas L; Rubio A; Arellano-Rodrigo E; Hernández Boluda JC; Papaleo N; Caballero G; Martínez C; Ferrer-Marín F; Mata MI; Pérez-Encinas M; Durán MA; Alonso JM; Carreño-Tarragona G; Alonso JM; Noya S; Magro E; Pérez R; López-Guerra M; Pastor-Galán I; Cervantes F; Besses C; Colomo L; Rozman M
J Clin Pathol; 2018 Nov; 71(11):975-980. PubMed ID: 29934356
[TBL] [Abstract][Full Text] [Related]
37. Detection of CALR and MPL Mutations in Low Allelic Burden JAK2 V617F Essential Thrombocythemia.
Usseglio F; Beaufils N; Calleja A; Raynaud S; Gabert J
J Mol Diagn; 2017 Jan; 19(1):92-98. PubMed ID: 27855276
[TBL] [Abstract][Full Text] [Related]
38. Homomultimerization of mutant calreticulin is a prerequisite for MPL binding and activation.
Araki M; Yang Y; Imai M; Mizukami Y; Kihara Y; Sunami Y; Masubuchi N; Edahiro Y; Hironaka Y; Osaga S; Ohsaka A; Komatsu N
Leukemia; 2019 Jan; 33(1):122-131. PubMed ID: 29946189
[TBL] [Abstract][Full Text] [Related]
39. [Not Available].
Mosca M; Vertenoeil G; Toppaldoddi KR; Plo I; Vainchenker W
Bull Cancer; 2016 Jun; 103(6 Suppl 1):S16-28. PubMed ID: 27494969
[TBL] [Abstract][Full Text] [Related]
40. MPLW515L mutation in acute megakaryoblastic leukaemia.
Hussein K; Bock O; Theophile K; Schulz-Bischof K; Porwit A; Schlue J; Jonigk D; Kreipe H
Leukemia; 2009 May; 23(5):852-5. PubMed ID: 19194467
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]